Table 1. Baseline characteristics of 64 metastatic colorectal cancer patients.
| Patients No. (%) (N = 64) |
|
|---|---|
| Age, years Mean + SD (range) ≧65 years <65 years |
60 (30–83) 28 (43.8) 36 (56.3) |
| Gender Male Female |
40 (62.5) 24 (37.5) |
| Chemotherapy/targeted therapy cycle =6 ≥7 |
28 (43.8) 36 (56.2) |
| Metastectomy location Liver Lung Ovary |
46 (71.9) 15 (23.4) 3 (4.7) |
| Primary lesion site Right-side Left-side |
7 (10.9) 57 (89.1) |
| Synchronous/Metachronous Synchronous Metachronous |
36 (56.3) 28 (43.8) |
| Operation Operation time (min, medium + SD) (range) Estimated blood loss (ml, medium + SD) (range) |
150 + 109.73 (50–645) 100 + 154.73 (5–700) |
|
RAS status Wild Mutant |
53 (82.8) 11 (17.2) |
| Pre-treatment CEA (ng/ml) ≧5 <5 Post-treatment CEA (ng/ml) ≧5 <5 |
45 (70.3) 19 (29.7) 28 (43.8) 36 (56.3) |
| Type of targeted therapy Cetuximab Bevacizumab |
39 (60.9) 25 (39.1) |
| Efficacy Response (CR + PR) Non-response (SD + PD) |
47 (73.4) 17 (26.6) |
| Progression Yes No |
35 (54.7) 29 (45.3) |
| Survival Yes No |
41 (64.1) 23 (35.9) |
| Grade III or more adverse effect Yes No |
10 (15.6) 54 (84.4) |
Note: CEA = carcinoembryonic antigen; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.